AstraZeneca Pharma India gets CDSCO nod to import pharmaceutical formulations of Eculizumab Ruchika Sharma17 Jan 2025 1:32 PM ISTBangalore: AstraZeneca Pharma India Limited has received permission to import pharmaceutical formulations of new drug for sale or for...
Danicopan therapy with eculizumab or ravulizumab may reduce breakthrough hemolysis events in PNH patients: Study Dr Riya Dave19 Dec 2024 8:30 AM ISTResearchers have discovered that with the dual inhibition of C5 and factor D, patients with paroxysmal nocturnal hemoglobinuria (PNH) develop fewer...
Roche gets USFDA nod for chronic blood disorder treatment Crovalimab Ruchika Sharma23 Jun 2024 4:30 PM ISTRoche has received approval from the U.S. Food and Drug Administration (USFDA) for Crovalimab for the treatment of chronic blood...
KP104 shows Robust Efficacy in Paroxysmal Nocturnal Hemoglobinuriain Phase 2 trial results Dr. Kamal Kant Kohli20 Jun 2024 3:30 AM ISTAccording to Phase 2 results, KP104 exhibits optimal long-term safety and efficacy for complement inhibitor-naive patients with paroxysmal nocturnal...
AstraZeneca Gets CDCSO Panel Nod to Import, market Eculizumab to treat Paroxysmal Nocturnal Hemoglobinuria Dr. Divya Colin29 April 2024 6:00 PM ISTNew Delhi: Noting that there is an unmet medical need in India, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control...
Novartis Fabhalta gets positive CHMP opinion as first oral monotherapy for adult patients with paroxysmal nocturnal hemoglobinuria Ruchika Sharma24 March 2024 2:30 PM ISTBasel: Novartis has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a...
Oral Iptacopan monotherapy improves outcomes in patients with paroxysmal nocturnal hemoglobinuria: NEJM Medha Baranwal15 March 2024 9:15 PM ISTFrance: A recent study has shown improved clinical and hematologic outcomes with iptacopan treatment in anti-C5-treated patients with persistent...
FDA approves Fabhalta as oral treatment for paroxysmal nocturnal hemoglobinuria Jacinthlyn Sylvia11 Dec 2023 11:15 AM ISTThe US Food and Drug Administration has approved Fabhalta (iptacopan) as first oral monotherapy for adults suffering from paroxysmal nocturnal...
Novartis gets USFDA nod for Fabhalta for adults with paroxysmal nocturnal hemoglobinuria Ruchika Sharma7 Dec 2023 11:43 AM ISTBasel: Novartis has announced that the U.S. Food and Drug Administration (FDA) has approved Fabhalta (iptacopan) as the first oral monotherapy for the...
Iptacopan monotherapy improves outcome against paroxysmal nocturnal hemoglobinuria: Study Medical Dialogues Editorial Team28 May 2022 11:00 AM ISTKorea: A recent trial led by Jun Ho Jang and colleagues found that iptacopan monotherapy resulted in normalization of hemolytic indicators and quick...
COVID-19 vaccination induces Paroxysmal nocturnal hemoglobinuria flare: Case report Medical Dialogues Editorial Team19 April 2022 9:15 AM ISTDr Kawthar Jarrah at Division of Hematology-Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon...
COVID-19 vaccines may increase hemolysis risk in PNH patients: Study Dr Satabdi Saha26 Jun 2021 7:45 AM ISTAccording to recent research reports published in Blood ,Patients with paroxysmal nocturnal hemoglobinuria (PNH) who receive vaccination for...
